Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04832425
Other study ID # PRAX-114-213
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date March 30, 2021
Est. completion date May 5, 2022

Study information

Verified date July 2022
Source Praxis Precision Medicines
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of PRAX-114 in participants with moderate to severe major depressive disorder (MDD). Participants will be randomized to receive 28 days of either 40 mg PRAX-114 or placebo in a 1:1 ratio.


Recruitment information / eligibility

Status Completed
Enrollment 216
Est. completion date May 5, 2022
Est. primary completion date May 5, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Recurrent MDD diagnosis with a current episode duration of at least 8 weeks and no more than 24 months. 2. HAM-D17 total score of =23 at Screening and Baseline. 3. Body mass index (BMI) between 18 and 38 kg/m2 (inclusive). Exclusion Criteria: 1. Lifetime history of seizures, including febrile seizures. 2. Neurodegenerative disorder (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, or Huntington's disease). 3. Lifetime history of bipolar disorder, a psychotic disorder (eg, schizophrenia or schizoaffective disorder), or obsessive compulsive disorder or a history of a psychotic mood episode in last 2 years. 4. Any current psychiatric disorder (other than MDD). 5. Lifetime history of treatment resistant depression. 6. Received electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS) within the last year or transcranial magnetic stimulation (TMS) within the last 6 months prior to Screening. 7. Daily consumption of more than 2 standard alcohol-containing beverages for males or more than 1 standard alcohol-containing beverages for females.

Study Design


Intervention

Drug:
PRAX-114
40 mg once daily
Placebo
Placebo once daily

Locations

Country Name City State
Australia Praxis Research Site Noble Park Victoria
United States Praxis Research Site Allentown Pennsylvania
United States Praxis Research Site Atlanta Georgia
United States Praxis Research Site Austin Texas
United States Praxis Research Site Berlin New Jersey
United States Praxis Research Site Cedarhurst New York
United States Praxis Research Site Charlottesville Virginia
United States Praxis Research Site Chicago Illinois
United States Praxis Research Site Dayton Ohio
United States Praxis Research Site Decatur Georgia
United States Praxis Research Site Everett Washington
United States Praxis Research Site Gaithersburg Maryland
United States Praxis Research Site Garden Grove California
United States Praxis Research Site Jacksonville Florida
United States Praxis Research Site Lafayette California
United States Praxis Research Site Las Vegas Nevada
United States Praxis Research Site Lemon Grove California
United States Praxis Research Site Marlton New Jersey
United States Praxis Research Site Media Pennsylvania
United States Praxis Research Site Memphis Tennessee
United States Praxis Research Site O'Fallon Missouri
United States Praxis Research Site Oceanside California
United States Praxis Research Site Orange City Florida
United States Praxis Research Site Orlando Florida
United States Praxis Research Site Phoenix Arizona
United States Praxis Research Site Pico Rivera California
United States Praxis Research Site Redlands California
United States Praxis Research Site Rochester New York
United States Praxis Research Site San Antonio Texas
United States Praxis Research Site Staten Island New York
United States Praxis Research Site Worcester Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Praxis Precision Medicines

Countries where clinical trial is conducted

United States,  Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in 17-Item Hamilton Depression Rating Scale (HAM-D17) total score at Day 15 The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. 15 days
Secondary Change from baseline in HAM-D17 total score at Day 29 The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. 29 days
Secondary Change from baseline in HAM-D17 total score at all other time points The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. 8 days, 22 days, 36 days, and 43 days
Secondary Change from baseline in Clinical Global Impression-Severity (CGI-S) score at Day 15 and all other time points The CGI-S assesses the clinician's impression of the participant's current depression symptoms. The clinician should use his/her total clinical experience with this patient population and rate the current severity of the participant's mental illness on a 7-point scale from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients). 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary Clinical Global Impression-Improvement (CGI-I) score at Day 15 and all other time points The CGI-I assesses the participant's improvement (or worsening). The clinician is required to assess the participant's condition relative to Baseline (Day 1) on a 7-point scale from 1 (Very much improved) to 7 (Very much worse). 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary HAM-D17 response (reduction from baseline score of =50%) at Day 15, Day 29, and all other time points The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary HAM-D17 remission (total score of =7) at Day 15, Day 29, and all other time points The HAM-D17 is a depression rating scale consisting of 17 items; 9 items are scored on a 5-point scale (ranging from 0 to 4), and 8 items are scored on a 3-point scale (ranging from 0 to 2). The total score of the 17 items ranges from 0 to 52 with higher scores indicating greater depression. Therefore, a decrease in the total score or on individual item scores indicates improvement. 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary Change from baseline in the Symptoms of Depression Questionnaire (SDQ) total and sub-scale scores at Day 15 and all other time points The SDQ is a 44-item, self-report scale assessing the severity of symptoms across several subtypes of depression. Items are scored on a 7-point scale (ranging from 1 to 6). The SDQ total score is the sum of all 44 item scores and ranges from 44 to 264 with higher scores indicating worse symptoms. 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary Patient Global Impression-Improvement (PGI-I) score at Day 15 and all other time points The PGI-I scale is a global self-assessment used to rate the response of a participant's condition to therapy or intervention. It consists of 1 question that asks the participant to rate their current condition compared to how it was prior to beginning treatment on a scale of 1 (very much better) to 7 (very much worse). 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary Change from baseline in the Work and Social Adjustment Scale (WSAS) at Day 15 and all other time points The WSAS assesses the degree to which mental health problems interfere with day-to-day functioning in 5 domains: work, social leisure activities, private leisure activities, home- management, and personal relationships. The WSAS total score is the sum of the 5 item scores and ranges from 0 to 40, with higher scores indicating poorer adjustment. 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary Change from baseline in the 12-Item Short Form Survey (SF-12) at Day 15 and all other time points The SF-12 is composed of 12 questions covering 8 dimensions of health: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Total scores range from 0 (worse health) to 100 (better health). 8 days, 15 days, 22 days, 29 days, 36 days, and 43 days
Secondary Incidence and severity of Adverse Events (AE) An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study drug, whether or not considered related to the study drug. 43 days
Secondary Incidence of AEs by preferred term The incidence of AEs will be reported by preferred term, including any terms related to clinically significant changes in body temperature, pulse rate, respiratory rate, blood pressure (systolic and diastolic), clinical laboratory measures (chemistry, hematology, urinalysis, and coagulation), and electrocardiogram parameters (heart rate, PR, QRS, QT, and corrected QT intervals). Up to 43 days
Secondary Incidence of Columbia-Suicide Severity Rating Scale (C-SSRS) measured suicidal ideation or behavior The C-SSRS is composed of 5 yes/no questions addressing suicidal behavior and 5 yes/no questions addressing suicidal ideation, with sub-questions assessing the severity. Incidence is measured as the number of "yes" answers indicating the presence of suicidal ideation or behavior. Up to 43 days
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A